Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland.

Abstract excerpt

While KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), KRAS-mutant tumors have long been considered difficult to treat and thus, an unmet need still remains. Partly due to the lack of targeted treatments, comprehensive real-world description of NSCLC patients with KRAS mutation is still largely missing in Finland. In this study, all adult patients diagnosed with locally advanced...

Topics

• Humans
• Carcinoma, Non-Small-Cell Lung
• Finland
• Proto-Oncogene Proteins p21(ras)
• Lung Neoplasms
• Female